The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $363,602 Project Grant (CFDA 93.853 - Extramural Research Programs in the Neurosciences and Neurological Disorders) to Tulane University to develop improved screening tools for anti-seizure medications using a Drosophila (fruit fly) model of pharmacoresistant epilepsy.
The key products and services to be delivered under this grant include:
- Enhancing the efficiency of anti-seizure drug screening in the Drosophila model using multi-fly video tracking and electrophysiology techniques (R61 phase).
- Leveraging the improved screening tools to evaluate a large collection of over 3,500 previously approved drugs for potential repurposing as treatments for pharmacoresistant epilepsy (R33 phase).
This project aims to identify new drug candidates that can be repurposed to treat pharmacoresistant forms of epilepsy, which affect many individuals. The grant will also produce powerful new tools for in vivo screening of anti-seizure drugs using Drosophila models of human epilepsy.
Generated 3/4/25, 7:06 AM